The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

kolltan.com

Founded Year

2007

Stage

Acquired | Acquired

Total Raised

$135M

Valuation

$0000 

About Kolltan Pharmaceuticals

Kolltan Pharmaceuticals is a clinical-stage company focused on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases (RTKs). Focused primarily in oncology and backed by prominent thought leaders in RTK biology, Kolltan has reported clinical and preclinical data that its drug candidates can help overcome tumor resistance mechanisms associated with current tyrosine kinase inhibitors and seen in patients who have failed other cancer therapies.

Kolltan Pharmaceuticals Headquarter Location

300 George Street Suite 530

New Haven, Connecticut, 06511,

United States

203-773-3000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Kolltan Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kolltan Pharmaceuticals is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Kolltan Pharmaceuticals Patents

Kolltan Pharmaceuticals has filed 8 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/10/2015

8/18/2020

Tyrosine kinase receptors, Experimental cancer drugs, Monoclonal antibodies, Clusters of differentiation, Transcription factors

Grant

Application Date

4/10/2015

Grant Date

8/18/2020

Title

Related Topics

Tyrosine kinase receptors, Experimental cancer drugs, Monoclonal antibodies, Clusters of differentiation, Transcription factors

Status

Grant

Latest Kolltan Pharmaceuticals News

Kolltan Pharmaceuticals Inc. Mergers Acquisitions MA Partnerships Alliances and Investment Report Report Updated 28072018 Prices from USD $350

Oct 7, 2018

Printed From BioPortfolio.com Kolltan Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 28072018] Prices from USD $350 20:46 EDT 6 Oct 2018 | BioPortfolio Reports Kolltan Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Summary Marketline's Kolltan Pharmaceuticals, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Kolltan Pharmaceuticals, Inc. since January2007. Synopsis Marketline's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlights This report includes Kolltan Pharmaceuticals, Inc.'s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed. The profile also includes detailed deal reports for all MA, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Kolltan Pharmaceuticals, Inc.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed. Scope Provides intelligence on Kolltan Pharmaceuticals, Inc.'s MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Kolltan Pharmaceuticals, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Kolltan Pharmaceuticals, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. Reasons to buy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Kolltan Pharmaceuticals, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News

You May Also Like

K
Kanisa Pharmaceuticals

Kanisa Pharmaceuticals is a pharmaceutical company focused on the acquisition, development and commercialization of therapeutics in the field of oncology.

VGXI Logo
VGXI

VGXI is a contract manufacturer of plasmid DNA. The company delivers flexibility, experience, reliability, and value to clients’ challenging programs. The company’s cGMP and non-cGMP products have passed rigorous international regulatory reviews.

A
Adastra Pharmaceuticals

Adastra Pharmaceuticals is a private, clinical-stage biopharmaceutical company committed to providing responsible solutions to advance patient care in oncology. Its vision is to identify, develop, and deliver to patients important new therapies for diseases with significant unmet needs. This commitment is epitomized by its lead clinical candidate, zotiraciclib, which is initially being developed for the treatment of high-grade gliomas (HGG) and diffuse intrinsic pontine glioma (DIPG), two forms of brain cancer characterized by Myc overexpression. Adastra possesses a rich history of institutional and academic collaboration, including ongoing clinical research programs with the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC).

A
Ansata Therapeutics

Founded in early 2002 by Avalon Ventures and Domain Associates, Ansata Therapeutics is developing & commercializing novel medicines that capitalize on the Company's industry- leading expertise and intellectual property in molecular transduction. Ansata has several preclinical programs under development in the oncology and neurodegenerative disease areas. The company strives to rapidly advance lead compounds from late-stage preclinical research into clinical development by leveraging its proprietary knowledge of common dermatological diseases.

M
Metronome Therapeutics

Metronome Therapeutics is developing oncology drugs

T
Tolera Therapeutics

Tolera Therapeutics is developing targeted therapies for immune suppression and immune tolerance, designed for use in organ transplant surgeries and other medical settings requiring safer, more targeted immune modulation. The goal is to provide improved induction therapy with a better safety profile than current treatment options. The company's technology, which stems from organ transplant research done at the Cleveland Clinic, has been undergoing clinical research and has been tested in humans. The regulatory pathway is expected to bring a product to market in 2012.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.